ARNI in cardiovascular disease: current evidence and future perspectives

Area of Science:

• Cardiology
• Pharmacology

Background:

• Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are standard treatments for cardiovascular disease and heart failure (HF).
• Sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is established for treating heart failure with reduced ejection fraction (HFrEF) following the PARADIGM-HF trial.

Purpose of the Study:

• To review current literature and future perspectives on the use of ARNI in various cardiovascular disorders.
• To update on the established role of ARNI in HFrEF and its expanding applications.

Main Methods:

• Literature review of current studies on ARNI.
• Analysis of evidence from trials like PARADIGM-HF.
• Exploration of ARNI's efficacy in diverse patient subsets and conditions.

Main Results:

• The PARADIGM-HF trial established a strong evidence base for ARNI in HFrEF treatment across various patient subsets.
• ARNI is being investigated and utilized in numerous cardiovascular conditions beyond HFrEF.

Conclusions:

• ARNI, particularly sacubitril-valsartan, has a significant role in managing HFrEF.
• The therapeutic applications of ARNI are expanding to encompass a broader range of cardiovascular disorders, warranting further investigation.